Cabaletta Bio (CABA) Preferred Stock Liabilities (2018 - 2019)
Cabaletta Bio (CABA) recorded quarterly Preferred Stock Liabilities of $98.0 million in Q3 2019, little changed quarter-over-quarter from $98.0 million in Q2 2019.
Cabaletta Bio (CABA) Preferred Stock Liabilities (2018 - 2019) Analysis & Trends
Cabaletta Bio's Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $98.0 million for Q3 2019.
- In Q3 2019, Preferred Stock Liabilities changed N/A year-over-year to $98.0 million; the TTM figure through Sep 2019 stood at $98.0 million (changed N/A YoY), while the FY2018 annual figure was $43.9 million, changed N/A from the prior year.
- Preferred Stock Liabilities was $98.0 million for Q3 2019 at Cabaletta Bio, roughly flat from $98.0 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $98.0 million in Q2 2019 to a low of $43.9 million in Q4 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Cabaletta Bio | 151.84 Mn | 18.24 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2019 | 97.95 Mn |
| Jun 30, 2019 | 97.95 Mn |
| Dec 31, 2018 | 43.92 Mn |